The aim of the present work was to develop methods for the preparation of a nanosomal form of low-sialylated recombinant human erythropoietin (ls-rhEPO), which has neurotropic antihemorrhagic activity. Measurements were made of the sorption of erythropoietin to nanoparticles made of lactic acid homopolymer or lactic acid/glycolic acid copolymer, mean nanoparticle size, and the resistance of the resulting complex to aggregation. The most effective sorption (greater than 80%) was achieved using a copolymer with equal proportions of lactic and glycolic acids (50:50). Experiments using an intracerebral post-traumatic hematoma model in rats demonstrated that nanosomal ls-rhEPO had neuroprotective actions, based on its ability to decrease death in the experimental animals (77.8% survived, which was 40% more than in the control group). Nanosomal ls-rhEPO was found to have no effect on hematopoiesis in conditions of chronic administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
M. Brines, M. S. Patel, P. Villa, et al., Proc. Natl. Acad. Sci. USA, 105, 10925 – 10930 (2008).
Q. Fan, K. K. Leuther, C. P. Holmes, et al., Exp. Hematol., 34, 1303 – 1311 (2006).
N. C. Wrighton, F. X. Farrel, R. Chang, et al., Science, 273, 458 – 463 (1996).
S. É. Gel’perina and V. I. Shvets, Biotekhnologiya, 3, 8 – 23 (2009).
D. R. Calaria, V. Sharma, V. Beniwal, et al., Pharm. Res., 26, 492 – 501 (2009).
X. Gao, B. Wu, Q. Zhang, et al., J. Control Rel., 121, 156 – 167 (2007).
K. B. Kurachmaeva, I. A. Djindjikhashvili, and V. E. Petrovetal, J. Drug Target, 17, 564 – 574 (2009).
S. Wagner, J. Kufleitner, A. Zensi, et al., PLoS One, 5 (2010).
S. Wohlfart, S. Gelperina, and J. Kreuter, “J. Control Rel., 161, 264 – 273 (2012).
V. Yu. Balaban’yan, I. N. Solev, O. S. Elizarova, et al., Ékpserim. Klin. Farmakol., 74(10), 12 – 15 (2011).
X. Rong, X. Mo, T. Ren, et al.,. Eur. J. Pharmacol., 42, 334 – 342 (2011).
J. He, M. Feng, X. Zhou, et al., Int. J. Pharm., 416, 69 – 76 (2011).
M. Ueda and J. Kreuter, Microencapsulation, 14, No. 5, 593 – 605 (1997).
T. L. Garibova, I. P. Galaeva, T. A. Voronina, et al., Ékpserim. Klin. Farmakol., 66(2), 45 – 58 (2003).
A. N. Makarenko, N. S. Kositsin, S. V. Karpenko, and V. A. Mishina, Patent No. 1767518 (1999).
S. I. Gulyaeva, M. Yu. Meshcheryakova, and K. V. Demesh, A Big Practical Guide in Hematology [in Russian], VGU Press, Voronezh (2009), pp. 10 – 11.
D. T. Birnbaum, J. D. Kosmala, and L. Brannon-Peppas, J. Nanoparticle Res., 2(2), 173 – 181 (2000).
M. Etcheverrigaray, N. Ceaglio, M. Mattio, et al., BMC Proc., 5(8), 3 (2011).
The authors would like to thank ZAO FarmFirma Soteks for assistance and financial support.
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 46, No. 10, pp. 49 – 52, October, 2012.
Rights and permissions
About this article
Cite this article
Elizarova, O.S., Balaban’yan, V.Y., Shipulo, E.V. et al. Efficacy of a new colloidal form of low-sialylated polylactide-based erythropoietin in experimental hemorrhagic stroke in rats. Pharm Chem J 46, 626–629 (2013). https://doi.org/10.1007/s11094-013-0858-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-013-0858-9